About NAT Diagnostics
NAT Diagnostics is a company based in San Diego (United States) founded in 2015 was acquired by Becton Dickinson in May 2020. NAT Diagnostics has raised $4.41 million across 2 funding rounds from investors including BD. NAT Diagnostics operates in a competitive market with competitors including Cepheid, Prenetics, Karius, Day Zero Diagnostics and OpGen, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.41 M (USD)
in 2 rounds
-
Latest Funding Round
$1.5 M (USD), Seed
Nov 16, 2017
- Investors
-
Employee Count
Not available
-
Acquired by
Becton Dickinson
(May 15, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of NAT Diagnostics
NAT Diagnostics has successfully raised a total of $4.41M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.5 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NAT Diagnostics
NAT Diagnostics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include BD.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
BD is recognized for providing innovative medical technology solutions.
|
Locked | Locked | Locked |
Investor details for NAT Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NAT Diagnostics
Investment portfolio details for NAT Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NAT Diagnostics
Detailed financials for NAT Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nat Diagnostics Comparisons
Peer comparison for NAT Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NAT Diagnostics
NAT Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Prenetics, Karius, Day Zero Diagnostics and OpGen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of molecular diagnostic testing solutions
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
|
| Locked | Locked | Locked |
Genome sequencing diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| Locked | Locked | Locked |
Food safety technologies are provided for pathogen identification.
|
Detailed competitors of NAT Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nat Diagnostics
Complete news archive for NAT Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NAT Diagnostics
NAT Diagnostics was founded in 2015.
NAT Diagnostics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
NAT Diagnostics is a funded company, having raised a total of $4.41M across 2 funding rounds to date.
NAT Diagnostics was founded in 2015 and is based in San Diego, United States. Operations center on the development of point-of-care diagnostic devices for infectious diseases. Instrumentation is designed to provide results in 10 minutes, with costs under 800, and to meet CLIA-waiver standards while requiring no special training. Future efforts will target antibiotic resistance and oncology applications.
NAT Diagnostics's top competitors include Cepheid, Prenetics and Clear Labs.
NAT Diagnostics has 1 investor. Key investors include BD.